FisherBroyles’ FinTech and Blockchain Practice Group Featured American Lawyer

June 26th, 2018|FisherBroyles News|

FisherBroyles' FinTech and Blockchain practice group and its co-chairs, Adam Ettinger and Michael Pierson, featured in The American Lawyer article, Law Firms See Opportunity Pairing Blockchain and Securitization Expertise, June 25, 2018 Click here for article.

Partners Michael Khoury and Martin Robins contributed to the Spring 2018 Issue of Michigan Business Law Journal

June 22nd, 2018|FisherBroyles News|

Partners Michael Khoury and Martin Robins contributed to the Spring 2018 issue of The Michigan Business Law Journal, Technology Corner: Technology M&A Due Diligence: More to Consider. Read article here.

FisherBroyles’ Partner Philip Gallas Speaking on Section 232 Steel and Aluminum Tariffs on June 21 in Washington, DC

June 20th, 2018|FisherBroyles News, Trades and Customs|

Philip Gallas, a Partner in FisherBroyles' International Trade group, will be speaking as a panelist on the Section 232 Steel and Aluminum Tariffs that will be held in Washington, D.C. on June 21, 2018. This [...]

Partner Stu Panensky Authors Article on Technology Errors & Omissions (“Tech E&O”) for Professional Times Magazine

June 19th, 2018|FisherBroyles News, Technology|

Partner Stu Panensky authors article on Technology Errors & Omissions ("Tech E&O") for Professional Times Magazine. Titled, Does IT Go Without Saying?, Stu's article explores the standard of care and other legal issues relating to technology [...]

FisherBroyles Welcomes New DC Partners Richard A. Kirby and Beth-ann Roth

June 18th, 2018|FisherBroyles News|

FisherBroyles, LLP, the first and world’s largest distributed law firm partnership, is pleased to announce the addition of Richard A. Kirby and Beth-ann Roth as partners in the firm’s Washington, DC, office. The new partners [...]

FDA Releases Final Guidance on Drug and Medical Product Communications with Payors and Others

June 15th, 2018|FisherBroyles News, Pharmacy Law|

Earlier this week, the U.S. Food and Drug Administration (FDA) issued two new final guidance documents that provide greater clarity regarding the FDA’s position and recommendations on drug and medical product communications with payors, formulary [...]